NCT06638970View on ClinicalTrials.gov

Clinical Utility and Safety of Human Umbilical Cord Mesenchymal Stem Cell Secretome in Drug Resistant Epilepsy Single Center, Non-randomized, Phase I Clinical Trial

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions
EpilepsyDrugs Resistant Epilepsy
Interventions
DRUG

Secretome

3 ml Injection of secretome for 4 times two weeks apart

Trial Locations (1)

12810

Main Clinic Prof. Dadang Hawari, Jakarta

Sponsors

Lead Sponsor

Baermed
All Listed Sponsors
collaborator

Tarumanagara University

OTHER

lead

Baermed

OTHER

NCT06638970 - Clinical Utility and Safety of Human Umbilical Cord Mesenchymal Stem Cell Secretome in Drug Resistant Epilepsy Single Center, Non-randomized, Phase I Clinical Trial | Biotech Hunter | Biotech Hunter